***!!! NANOGEN - MELDUNG !!!*** - 500 Beiträge pro Seite
eröffnet am 21.09.00 15:11:19 von
neuester Beitrag 24.09.00 20:21:32 von
neuester Beitrag 24.09.00 20:21:32 von
Beiträge: 10
ID: 249.254
ID: 249.254
Aufrufe heute: 0
Gesamt: 982
Gesamt: 982
Aktive User: 0
ISIN: US6300751095 · WKN: 911841
Werte aus der Branche Nanotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 224,35 | +7,64 | |
| 1,8900 | +3,28 | |
| 30,00 | 0,00 | |
| 43,08 | 0,00 | |
| 1,3400 | 0,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4300 | -0,69 | |
| 5,0800 | -1,93 | |
| 75,70 | -2,27 | |
| 0,7621 | -4,39 | |
| 1,9550 | -4,75 |
Feedback
Hi all ...
das hab ich eben gefunden:
PR Newswire, 09/21/2000 07:16
National Cancer Institute Purchases Nanogen System
SAN DIEGO, Sept. 21 /PRNewswire/ -- Nanogen, Inc. (NASDAQ:NGEN) announces the purchase of a NanoChip(TM) Molecular Biology Workstation by the National Cancer Institute (NCI).
NanoChip(TM) system results were reported as 100% accurate with zero "no calls."
In addition, the NanoChip(TM) system corrected one result generated by an alternative technology.
http://www.quote.com/quotecom/news/story.asp?story=16751022
Das hört sich doch prima an ... hoffentlich reagiert der Kurs drauf!!!
Gruß
Fruitcake01
das hab ich eben gefunden:
PR Newswire, 09/21/2000 07:16
National Cancer Institute Purchases Nanogen System
SAN DIEGO, Sept. 21 /PRNewswire/ -- Nanogen, Inc. (NASDAQ:NGEN) announces the purchase of a NanoChip(TM) Molecular Biology Workstation by the National Cancer Institute (NCI).
NanoChip(TM) system results were reported as 100% accurate with zero "no calls."
In addition, the NanoChip(TM) system corrected one result generated by an alternative technology.
http://www.quote.com/quotecom/news/story.asp?story=16751022
Das hört sich doch prima an ... hoffentlich reagiert der Kurs drauf!!!
Gruß
Fruitcake01
Hi all ...
hier die gesamte Meldung:
PR Newswire, 09/21/2000 07:16
National Cancer Institute Purchases Nanogen System
SAN DIEGO, Sept. 21 /PRNewswire/ -- Nanogen, Inc. (NASDAQ:NGEN) announces the purchase of a NanoChip(TM) Molecular Biology Workstation by the National Cancer Institute (NCI). The sale follows a diligence process by the NCI involving alternative technologies for the detection of SNPs, including SNPs adjacent to secondary DNA structures.
Samples from a total of 48 patients, three SNPs per patient, were analyzed. NanoChip(TM) system results were reported as 100% accurate with zero "no calls." No calls result when there is a failure to obtain conclusive data from a given test sample. In addition, the NanoChip(TM) system corrected one result generated by an alternative technology. The three SNPs were in the genes for Interleukin 4, Interleukin 6 and Interleukin 4 receptor and represent two cytokines and a receptor. Cytokines are important components of the human immune system, the human body`s first line of defense in fighting infection and disease.
Dr. Stephen Chanock, M.D., of the NCI commented: "The National Cancer Institute aggressively pursues advanced technologies that can improve the ability to diagnose and treat illness. The NanoChip(TM) system may accelerate this process, allowing us to potentially use this same tool in both the research process and in the patient care process." Dr. Chanock`s laboratory is in the Immunocompromised Host Section, Pediatric Oncology Branch, at the Advanced Technology Center of the National Cancer Institute.
Howard C. Birndorf, Nanogen`s Chairman, President and CEO commented: "We have been impressed and encouraged by Dr. Chanock`s focus on translating clinically relevant genetic markers into clinical use as quickly as possible. The NCI appears to have a very thorough and practical approach that fits well with the benefits of the NanoChip(TM) system."
Nanogen recently began marketing its NanoChip(TM) Molecular Biology Workstation system to scientists and genomics laboratories, setting new standards for SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, "bridging" both the research and clinical diagnostic settings. For additional information please visit Nanogen`s web site at http://www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip system can be or will be further successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether the Company`s collaborations will continue to be funded and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K, as amended, for the year ended December 31, 1999 and subsequent reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. The Company may, at its discretion, issue additional announcements regarding orders or sales of it NanoChip system as it deems appropriate and as required by law. SOURCE Nanogen, Inc.
-0- 09/21/2000
CONTACT: Kieran T. Gallahue, President and CFO of Nanogen, Inc., 858-410-4600; or Anne Sunderland, Media, of Noonan-Russo Communications, 415-677-4455, Ext. 214, for Nanogen, Inc./
Web site: http://www.nanogen.com/
Companies or Securities discussed in this article: Symbol Name
NASDAQ:NGEN Nanogen, Inc. (NM)
© 2000 Quote.com, Inc., a Lycos Network site. All rights reserved.
Ich muß mich korrigieren ... die Meldung is ein HAMMER!!!
Gruß
Fruitcake01
hier die gesamte Meldung:
PR Newswire, 09/21/2000 07:16
National Cancer Institute Purchases Nanogen System
SAN DIEGO, Sept. 21 /PRNewswire/ -- Nanogen, Inc. (NASDAQ:NGEN) announces the purchase of a NanoChip(TM) Molecular Biology Workstation by the National Cancer Institute (NCI). The sale follows a diligence process by the NCI involving alternative technologies for the detection of SNPs, including SNPs adjacent to secondary DNA structures.
Samples from a total of 48 patients, three SNPs per patient, were analyzed. NanoChip(TM) system results were reported as 100% accurate with zero "no calls." No calls result when there is a failure to obtain conclusive data from a given test sample. In addition, the NanoChip(TM) system corrected one result generated by an alternative technology. The three SNPs were in the genes for Interleukin 4, Interleukin 6 and Interleukin 4 receptor and represent two cytokines and a receptor. Cytokines are important components of the human immune system, the human body`s first line of defense in fighting infection and disease.
Dr. Stephen Chanock, M.D., of the NCI commented: "The National Cancer Institute aggressively pursues advanced technologies that can improve the ability to diagnose and treat illness. The NanoChip(TM) system may accelerate this process, allowing us to potentially use this same tool in both the research process and in the patient care process." Dr. Chanock`s laboratory is in the Immunocompromised Host Section, Pediatric Oncology Branch, at the Advanced Technology Center of the National Cancer Institute.
Howard C. Birndorf, Nanogen`s Chairman, President and CEO commented: "We have been impressed and encouraged by Dr. Chanock`s focus on translating clinically relevant genetic markers into clinical use as quickly as possible. The NCI appears to have a very thorough and practical approach that fits well with the benefits of the NanoChip(TM) system."
Nanogen recently began marketing its NanoChip(TM) Molecular Biology Workstation system to scientists and genomics laboratories, setting new standards for SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, "bridging" both the research and clinical diagnostic settings. For additional information please visit Nanogen`s web site at http://www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip system can be or will be further successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether the Company`s collaborations will continue to be funded and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K, as amended, for the year ended December 31, 1999 and subsequent reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. The Company may, at its discretion, issue additional announcements regarding orders or sales of it NanoChip system as it deems appropriate and as required by law. SOURCE Nanogen, Inc.
-0- 09/21/2000
CONTACT: Kieran T. Gallahue, President and CFO of Nanogen, Inc., 858-410-4600; or Anne Sunderland, Media, of Noonan-Russo Communications, 415-677-4455, Ext. 214, for Nanogen, Inc./
Web site: http://www.nanogen.com/
Companies or Securities discussed in this article: Symbol Name
NASDAQ:NGEN Nanogen, Inc. (NM)
© 2000 Quote.com, Inc., a Lycos Network site. All rights reserved.
Ich muß mich korrigieren ... die Meldung is ein HAMMER!!!
Gruß
Fruitcake01
Hi all ...
... und der Kurs reagiert auch schon! +5,26% !!!
Na also ...
Gruß
Fruitcake01
... und der Kurs reagiert auch schon! +5,26% !!!
Na also ...
Gruß
Fruitcake01
Hi all ...
Nanogen in den USA vorbörslich schon +7,07% !!!
Es wird, es wird ...
Gruß
Fruitcake01
Nanogen in den USA vorbörslich schon +7,07% !!!
Es wird, es wird ...
Gruß
Fruitcake01
Hi all ...
... und da sind es schon 9,65%!!!
Gruß
Fruitcake01
... und da sind es schon 9,65%!!!
Gruß
Fruitcake01
Trading Spotlight
@ fruitcake01
wie wärs mit einer klitze kleinen Übersetzung.
Gruß X
wie wärs mit einer klitze kleinen Übersetzung.
Gruß X
Gute Idee Xedei, sinngem. Übersetzung reicht, denke ich
Hi all
Aktuell NGEN Minus 1.92%.??.Was soll man dazu noch sagen? Gute Meldungen verpuffen derzeit bei der miesen Börsenlage.
MfG Maxxtro
Aktuell NGEN Minus 1.92%.??.Was soll man dazu noch sagen? Gute Meldungen verpuffen derzeit bei der miesen Börsenlage.
MfG Maxxtro
Wie teuer ist ein nanogen system ?
Danke
F.C.
Danke
F.C.
Dran bleiben!NANOGEN ist eine von meiner Favoriten.Raubvogel.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,56 | |
| 0,00 | |
| 0,00 | |
| +0,87 | |
| 0,00 | |
| -0,69 | |
| -20,00 | |
| +0,90 | |
| 0,00 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 48 | ||
| 44 | ||
| 28 | ||
| 22 | ||
| 17 | ||
| 16 | ||
| 13 | ||
| 12 | ||
| 10 | ||
| 10 |
